Cryptococcal Antigen Lateral Flow Assay Test Market Segmentation:
Type Segment Analysis
Serum-based lateral flow assay tests segment for cryptococcal antigen lateral flow assay test market is expected to hold the largest share of 56% during the foreseen period. Serum-based assays identify particular markers or analytes in the bloodstream, providing useful diagnostic information. Numerous illnesses, such as cancer, autoimmune diseases, hormone abnormalities, and viral infections, can be diagnosed with these tests. Additionally, even at low concentrations, these assays are capable of precisely identifying and measuring target analytes in serum samples. Furthermore, the performance, repeatability, and throughput of serum-based assays have all increased with automation and standardization. To improve laboratory productivity and efficiency, healthcare facilities are progressively implementing automated methods for serum-based testing. Additionally, this test is essential to customized therapy because it helps determine the best course of action for each patient.
Instruments Segment Analysis
The kits and reagents segment for the cryptococcal antigen lateral flow assay test market is anticipated to hold the second-largest share of 53% during the projected period. With the use of these lateral flow kits, users may be more flexible in capturing and identifying any kind of analyte without having to apply the captured antibodies onto the test strip. These kits are utilized in medicines, animal health, environmental testing, feed and food testing, and crop and plant testing because of their versatility. During the projected period, new kit launches by leading manufacturers are expected to stimulate market growth. Also, the growing adoption of self-test kits for COVID-19 and other diseases is accelerating the growth of the segment. For instance, the Kenyan government has introduced two novel technologies, pre-exposure prophylaxis (PrEP) to prevent HIV infection and self-testing for HIV, in the hopes of taking the fight against the AIDS epidemic one step closer. HIV self-test kits are being provided by the government as part of the campaign at a low cost of about USD 8 per kit, which was negotiated in collaboration with the commercial sector and public and private health facilities.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
Instruments |
|
|
Location |
|
|
End-user |
|
